Capstone Therapeutics (CAPS) Stock Price, News & Analysis

Company Overview

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Key Stats

• Today's Range: $0.38 to $0.41
• 50-Day Range: $0.37 to $0.79
• 52-Week Range: $0.36 to $3.29
• Volume: 171,984 shs
• Average Volume: 5.69 million shs
• Market Capitalization: $5.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Capstone Therapeutics Stock Analysis - MarketRank™

Capstone Therapeutics scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Capstone Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Capstone Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Capstone Therapeutics has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.57% of the float of Capstone Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Capstone Therapeutics has a short interest ratio ("days to cover") of 0.53, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Capstone Therapeutics has recently decreased by 45.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Capstone Therapeutics does not currently pay a dividend.

Dividend Growth

Capstone Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Capstone Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

59.14% of the stock of Capstone Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.55% of the stock of Capstone Therapeutics is held by institutions.

CAPS Stock Analysis - Frequently Asked Questions

How have CAPS shares performed this year?

Capstone Therapeutics' stock was trading at $0.7279 on January 1st, 2026. Since then, CAPS stock has decreased by 47.4% and is now trading at $0.3829.

How were Capstone Therapeutics' earnings last quarter?

Capstone Therapeutics Corp. (NASDAQ:CAPS) announced its quarterly earnings data on Tuesday, November, 18th. The company reported ($0.35) EPS for the quarter. The business had revenue of $13.65 million for the quarter. Capstone Therapeutics had a negative net margin of 45.01% and a negative trailing twelve-month return on equity of 93.49%.
Read the conference call transcript.

When did Capstone Therapeutics IPO?

Capstone Therapeutics (CAPS) raised $5 million in an IPO on Thursday, March 6th 2025. The company issued 1,250,000 shares at a price of $4.00 per share.

How do I buy shares of Capstone Therapeutics?

Shares of CAPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Capstone Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Capstone Therapeutics investors own include Fulcrum Therapeutics (FULC), Ashford Hospitality Trust (AHT), Assertio (ASRT), Peabody Energy (BTU), PlayAGS (AGS), Astronics (ATRO) and

Company Calendar

• Last Earnings: 11/18/2025
• Today: 5/05/2026
• Next Earnings (Estimated): 5/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CAPS
• Previous Symbol: OTCMKTS:CAPS
• CIK: 887151
• Web: N/A
• Phone: (708) 371-0660
• Fax: 602-286-5300
• Employees: 38
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.23 million
• Net Margins: -45.01%
• Pretax Margin: -29.98%
• Return on Equity: -93.49%
• Return on Assets: -39.69%

Debt

• Debt-to-Equity Ratio: 0.75
• Current Ratio: 1.00
• Quick Ratio: 0.26

Sales & Book Value

• Annual Sales: $48.11 million
• Price / Sales: 0.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.37 per share
• Price / Book: 0.28

Miscellaneous

• Outstanding Shares: 14,440,000
• Free Float: 5,899,000
• Market Cap: $5.53 million
• Optionable: N/A
• Beta: -1.52